Inhibition of tumor implantation after laparoscopy by specific oligopeptides: a novel approach to adjuvant intraperitoneal therapy to prevent tumor implantation in an animal model.
OBJECTIVE
The development of intra-abdominal tumor spread and port-site metastases in urothelial cancer are still questions regarding the safety of laparoscopic methods for the resection of malignancies. Currently, the actual incidence of intra-abdominal tumor spread and port-site metastasis remains unknown. Herein, we investigated the influence of antiadhesive oligopeptides and cytotoxic agents (administered intraperitoneally) on implantation of a tumor cell suspension after laparoscopic surgery in an experimental model.


METHODS
Forty C57 bl6 mice underwent laparoscopy with CO(2) insufflation and instillation of a MB 49 syngenic urothelial tumor cell suspension into the abdominal cavity. Mice were randomly allocated to one of the following groups (n=10 mice per group), and all agents were administrated intraperitoneally: (1) control (phosphate-buffered saline); (2) unspecific oligopeptides; (3) specific oligopeptides; (4) mitomycin. The mice were sacrificed 14 d after the procedure, and the peritoneal cavity and port sites examined for the presence of tumor.


RESULTS
A significant reduction in tumor implantation and port-site metastases was observed in all treatment groups (specific oligopeptides and mitomycin). The oligopeptide group showed the best performance regarding body weight.


CONCLUSIONS
This study suggests that tumor implantation after laparoscopic surgery and port-site metastases might be prevented by the intraperitoneal administration of specific oligopeptides or cytotoxic agents. Moreover, oligopeptides, in comparison with mitomycin, caused less weight loss of the mice.
Jurczok
Andreas
A
Department of Urology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany. andreas.jurczok@medizin.uni-halle.de
Schneider
Astrid
A
Fornara
Paolo
P
D000704:Analysis of Variance; D000818:Animals; D016009:Chi-Square Distribution; D005260:Female; D007274:Injections, Intraperitoneal; D010535:Laparoscopy / Q000009:adverse effects*; D051379:Mice; D008810:Mice, Inbred C57BL; D016685:Mitomycin / Q000008:administration & dosage* / Q000494:pharmacology; D023421:Models, Animal; D009362:Neoplasm Metastasis / Q000517:prevention & control; D009366:Neoplasm Seeding; D009368:Neoplasm Transplantation; D009842:Oligopeptides / Q000008:administration & dosage* / Q000494:pharmacology; D011897:Random Allocation; D014407:Tumor Cells, Cultured
D009842:Oligopeptides; D016685:Mitomycin